Department of Psychology , University of New Mexico, Albuquerque, New Mexico.
Alcohol Clin Exp Res. 2013 Dec;37(12):2152-60. doi: 10.1111/acer.12205. Epub 2013 Jul 24.
The rate of participant attrition in alcohol clinical trials is often substantial and can cause significant issues with regard to the handling of missing data in statistical analyses of treatment effects. It is common for researchers to assume that missing data is indicative of participant relapse, and under that assumption, many researchers have relied on setting all missing values to the worst-case scenario for the outcome (e.g., missing = heavy drinking). This sort of single-imputation method has been criticized for producing biased results in other areas of clinical research, but has not been evaluated within the context of alcohol clinical trials, and many alcohol researchers continue to use the missing = heavy drinking assumption.
Data from the COMBINE study, a multisite randomized clinical trial, were used to generate simulated situations of missing data under a variety of conditions and assumptions. We manipulated the sample size (n = 200, 500, and 1,000) and dropout rate (5, 10, 25, 30%) under 3 missing data assumptions (missing completely at random, missing at random, and missing not at random). We then examined the association between receiving naltrexone and heavy drinking during the first 10 weeks following treatment using 5 methods for treating missing data (complete case analysis [CCA], last observation carried forward [LOCF], missing = heavy drinking, multiple imputation [MI], and full information maximum likelihood [FIML]).
CCA, LOCF, and missing = heavy drinking produced the most biased naltrexone effect estimates and standard errors under conditions that are likely to exist in randomized clinical trials. MI and FIML produced the least biased naltrexone effect estimates and standard errors.
Assuming that missing = heavy drinking produces biased results of the treatment effect and should not be used to evaluate treatment effects in alcohol clinical trials.
在酒精临床试验中,参与者的流失率通常很高,这会给处理统计分析中治疗效果的缺失数据带来重大问题。研究人员通常假设缺失数据表明参与者复发,根据这一假设,许多研究人员依赖于将所有缺失值设置为结果的最坏情况(例如,缺失=大量饮酒)。这种单一插补方法在临床研究的其他领域已被批评为产生有偏结果,但尚未在酒精临床试验的背景下进行评估,许多酒精研究人员仍继续使用缺失=大量饮酒的假设。
使用 COMBINE 研究的数据,该研究是一项多地点随机临床试验,根据各种条件和假设生成缺失数据的模拟情况。我们在 3 种缺失数据假设(完全随机缺失、随机缺失和非随机缺失)下操纵样本量(n=200、500 和 1000)和失效率(5%、10%、25%和 30%)。然后,我们使用 5 种缺失数据处理方法(完全案例分析[CCA]、最后一次观测结转[LOCF]、缺失=大量饮酒、多重插补[MI]和完全信息最大似然[FIML])检查接受纳曲酮与治疗后前 10 周内大量饮酒之间的关联。
CCA、LOCF 和缺失=大量饮酒在可能存在于随机临床试验中的条件下产生了最有偏纳曲酮效应估计值和标准误差。MI 和 FIML 产生了最少有偏的纳曲酮效应估计值和标准误差。
假设缺失=大量饮酒会产生治疗效果的有偏结果,不应用于评估酒精临床试验中的治疗效果。